116 related articles for article (PubMed ID: 30553852)
1. Secreted Gal-3BP is a novel promising target for non-internalizing Antibody-Drug Conjugates.
Giansanti F; Capone E; Ponziani S; Piccolo E; Gentile R; Lamolinara A; Di Campli A; Sallese M; Iacobelli V; Cimini A; De Laurenzi V; Lattanzio R; Piantelli M; Ippoliti R; Sala G; Iacobelli S
J Control Release; 2019 Jan; 294():176-184. PubMed ID: 30553852
[TBL] [Abstract][Full Text] [Related]
2. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
Keinänen O; Sarrett SM; Delaney S; Rodriguez C; Dayts EJ; Capone E; Sauniere F; Ippoliti R; Sala G; Iacobelli S; Zeglis BM
Mol Pharm; 2023 Jun; 20(6):3241-3248. PubMed ID: 37191353
[TBL] [Abstract][Full Text] [Related]
3. Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.
Gébleux R; Stringhini M; Casanova R; Soltermann A; Neri D
Int J Cancer; 2017 Apr; 140(7):1670-1679. PubMed ID: 27943268
[TBL] [Abstract][Full Text] [Related]
4. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
5. Association of Serum Galectin-3-Binding Protein and Metabolic Syndrome in a Chinese Adult Population.
Zhen S; Cai R; Yang X; Ma Y; Wen D
Front Endocrinol (Lausanne); 2021; 12():726154. PubMed ID: 34858323
[TBL] [Abstract][Full Text] [Related]
6. Acute hantavirus infection induces galectin-3-binding protein.
Hepojoki J; Strandin T; Hetzel U; Sironen T; Klingström J; Sane J; Mäkelä S; Mustonen J; Meri S; Lundkvist Å; Vapalahti O; Lankinen H; Vaheri A
J Gen Virol; 2014 Nov; 95(Pt 11):2356-2364. PubMed ID: 25013204
[TBL] [Abstract][Full Text] [Related]
7. Galectin-3 binding protein plasma levels are associated with long-term mortality in coronary artery disease independent of plaque morphology.
Gleissner CA; Erbel C; Linden F; Domschke G; Akhavanpoor M; Doesch AO; Buss SJ; Giannitsis E; Katus HA; Korosoglou G
Atherosclerosis; 2016 Aug; 251():94-100. PubMed ID: 27295060
[TBL] [Abstract][Full Text] [Related]
8. A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma.
Silverman AM; Nakata R; Shimada H; Sposto R; DeClerck YA
Cancer Res; 2012 May; 72(9):2228-38. PubMed ID: 22389450
[TBL] [Abstract][Full Text] [Related]
9. Galectin-3 Binding Protein and Galectin-1 Interaction in Breast Cancer Cell Aggregation and Metastasis.
Lin TW; Chang HT; Chen CH; Chen CH; Lin SW; Hsu TL; Wong CH
J Am Chem Soc; 2015 Aug; 137(30):9685-93. PubMed ID: 26168351
[TBL] [Abstract][Full Text] [Related]
10. Antibody drug conjugates: Progress, pitfalls, and promises.
Mukherjee A; Waters AK; Babic I; Nurmemmedov E; Glassy MC; Kesari S; Yenugonda VM
Hum Antibodies; 2019; 27(1):53-62. PubMed ID: 30223393
[TBL] [Abstract][Full Text] [Related]
11. Effect of linker variation on the stability, potency, and efficacy of carcinoma-reactive BR64-doxorubicin immunoconjugates.
Trail PA; Willner D; Knipe J; Henderson AJ; Lasch SJ; Zoeckler ME; TrailSmith MD; Doyle TW; King HD; Casazza AM; Braslawsky GR; Brown J; Hofstead SJ; Greenfield RS; Firestone RA; Mosure K; Kadow KF; Yang MB; Hellström KE; Hellström I
Cancer Res; 1997 Jan; 57(1):100-5. PubMed ID: 8988048
[TBL] [Abstract][Full Text] [Related]
12. Impact of drug conjugation on pharmacokinetics and tissue distribution of anti-STEAP1 antibody-drug conjugates in rats.
Boswell CA; Mundo EE; Zhang C; Bumbaca D; Valle NR; Kozak KR; Fourie A; Chuh J; Koppada N; Saad O; Gill H; Shen BQ; Rubinfeld B; Tibbitts J; Kaur S; Theil FP; Fielder PJ; Khawli LA; Lin K
Bioconjug Chem; 2011 Oct; 22(10):1994-2004. PubMed ID: 21913715
[TBL] [Abstract][Full Text] [Related]
13. Improving the therapeutic index in cancer therapy by using antibody-drug conjugates designed with a moderately cytotoxic drug.
Govindan SV; Cardillo TM; Rossi EA; Trisal P; McBride WJ; Sharkey RM; Goldenberg DM
Mol Pharm; 2015 Jun; 12(6):1836-47. PubMed ID: 25402018
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
15. Development of novel anti-CD19 antibody-drug conjugates for B-cell lymphoma treatment.
Li Z; Wang M; Yao X; Li H; Li S; Liu L; Yu D; Li X; Fang J; Huang C
Int Immunopharmacol; 2018 Sep; 62():299-308. PubMed ID: 30048860
[TBL] [Abstract][Full Text] [Related]
16. Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice.
Rossin R; Versteegen RM; Wu J; Khasanov A; Wessels HJ; Steenbergen EJ; Ten Hoeve W; Janssen HM; van Onzen AHAM; Hudson PJ; Robillard MS
Nat Commun; 2018 May; 9(1):1484. PubMed ID: 29728559
[TBL] [Abstract][Full Text] [Related]
17. Galectin-3-binding protein: A multitask glycoprotein with innate immunity functions in viral and bacterial infections.
Loimaranta V; Hepojoki J; Laaksoaho O; Pulliainen AT
J Leukoc Biol; 2018 Oct; 104(4):777-786. PubMed ID: 29882603
[TBL] [Abstract][Full Text] [Related]
18. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
[TBL] [Abstract][Full Text] [Related]
19. Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.
Dimasi N; Fleming R; Zhong H; Bezabeh B; Kinneer K; Christie RJ; Fazenbaker C; Wu H; Gao C
Mol Pharm; 2017 May; 14(5):1501-1516. PubMed ID: 28245132
[TBL] [Abstract][Full Text] [Related]
20. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies.
Asundi J; Crocker L; Tremayne J; Chang P; Sakanaka C; Tanguay J; Spencer S; Chalasani S; Luis E; Gascoigne K; Desai R; Raja R; Friedman BA; Haverty PM; Polakis P; Firestein R
Clin Cancer Res; 2015 Jul; 21(14):3252-62. PubMed ID: 25862760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
